focus -WSS

focus

author：comprehensive 2025-09-29 01:07:20 - browse：35783

PHILADELPHIA — Novo Nordisk, which has dominated the diabetes and obesity markets with its blockbuster drugs Ozempic and Wegovy, now also wants to be a major player in heart disease.

The landmark Select trial presented over the weekend — which showed Wegovy significantly cut the risk of heart complications — is just one of many efforts by the Danish drugmaker to expand into the cardiovascular space. It’s also developing several treatments specific to heart disease and is acquiring a medication for high blood pressure.

“We have a clear vision of being an established cardiovascular company, just as we see ourselves as leaders in diabetes and obesity,” Martin Lange, Novo’s executive vice president of development, said in an interview here at the American Heart Association conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Wegovy cuts risk of cardiovascular events by 20%, study finds

hotspot

leisure time

Wikipedia

WSS

What nurses really want: sufficient staffing for patient care

Google says AlphaFold 3 can map a vast universe of biomolecules

More regulation could be coming for drug ads

Apple Watch's A

FTX founder Sam Bankman

CDC launches VaccineFinder tool to locate Covid

knowledge

focus

explore

Medical leaders decry Supreme Court decision on affirmative action

H5N1 bird flu: what we're starting to learn about infection in cows

Novavax promises a turnaround & Lilly roils the obesity market

Readout LOUD podcast: What to know about H5N1 bird flu

How to save PrEP access — and even expand it

Travel bans should be based on evidence, not politics or fear

Psychedelics group wrestles with new pharma identity

'Of course' Trump lost the 2020 election, DeSantis says after years of hedging

United colonoscopy coverage change 'may cost lives,' doctors say

Dairy farmers resist CDC push for PPE against bird flu virus

focus

Dairy farmers resist CDC push for PPE against bird flu virus

Readout Newsletter: Sanofi, Novavax, Maze x Shionogi news

More regulation could be coming for drug ads

H5N1 communication has been strictly for the birds

Judge rejects Trump's counterclaim against E. Jean Carroll

Study: Adult vaccinations pay for themselves in societal benefits

hotspot

leisure time

Wikipedia

hotspot